. Author manuscript; available in PMC: 2021 Jun 13.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 Aug 26;19(12):763–775.e2. doi: 10.1016/j.clml.2019.08.004

Table 5.

Comparison of Health Care Costs per Patient per Month Between Ibrutinib and CIT and Between Ibrutinib and BR During the First 6-month Period ^{b, c}

	MMCD^d	95% CI^e	P Value^e
Ibrutinib versus CIT
Monthly all-cause total health care costs, US $2017	−8,365	−9,975 to −6,464	<.0001^a
Medical costs	−15,664	−17,399 to −13,827	<.0001^a
Inpatient costs	−349	−1,206 to 730	.4880
Outpatient costs	−14,875	−16,155 to −13,510	<.0001^a
Antineoplastic/CIT drug costs	−9,362	−10,122 to −8,526	<.0001^a
Costs related to the antineoplastic/CIT drug administration	−3,744	−4,560 to −2,987	<.0001^a
Other outpatient costs	−1,769	−2,525 to −1,000	<.0001^a
ER costs	−238	−427 to 4	.0520
Other services costs	−201	−348 to −57	.0160^a
Pharmacy costs	7,299	6,713 to 8,042	<.0001^a
Monthly cancer-related total health care costs,^f US $2017	−8,301	−9,901 to −6,534	<.0001^a
Medical costs	−15,497	−17,224 to −13,672	<.0001^a
Inpatient costs	−369	−1,229 to 724	.4840
Outpatient costs	−14,741	−16,012 to −13,458	<.0001^a
Antineoplastic/CIT drug costs	−9,292	−10,013 to −8,485	<.0001^a
Costs related to the antineoplastic/CIT drug administration	−3,722	−4,532 to −2,949	<.0001^a
Other outpatient costs	−1,726	−2,445 to −1,027	<.0001^a
ER costs	−203	−369 to 3	.0520
Other services costs	−184	−295 to −79	<.0001^a
Pharmacy costs	7,196	6,616 to 7,771	<.0001^a
Ibrutinib versus BR
Monthly all-cause total health care costs, US $2017	−10,896	−13,060 to −8,755	<.0001^a
Medical costs	−18,277	−20,340 to −16,165	<.0001^a
Inpatient costs	−331	−1,245 to 667	.4920
Outpatient costs	−17,523	−19,402 to −15,791	<.0001^a
Antineoplastic/CIT drug costs	−12,055	−13,352 to −10,980	<.0001^a
Costs related to the antineoplastic/CIT drug administration	−3,529	−4,775 to −2,396	<.0001^a
Other outpatient costs	−1,939	−3,015 to −905	<.0001^a
ER costs	−298	−676 to −49	.0120^a
Other services costs	−125	−276 to 95	.1480
Pharmacy costs	7,381	6,731 to 8,009	<.0001^a
Monthly cancer-related total health care costs,^f US $2017	−10,805	−12,829 to −8,767	<.0001^a
Medical costs	−18,088	−20,081 to −16,047	<.0001^a
Inpatient costs	−322	−1,258 to 684	.4920
Outpatient costs	−17,376	−19,173 to −15,729	<.0001^a
Antineoplastic/CIT drug costs	−11,990	−13,274 to −10,926	<.0001^a
Costs related to the antineoplastic/CIT drug administration	−3,517	−4,758 to −2,390	<.0001^a
Other outpatient costs	−1,869	−2,942 to −883	<.0001^a
ER costs	−265	−636 to −42	.0120^a
Other services costs	−124	−247 to 45	.0960
Pharmacy costs	7,283	6,671 to 7,839	<.0001^a

Abbreviations: BR = Bendamustine/rituximab; CI = confidence interval; CIT = chemoimmunotherapy; ER = emergency room; MMCD = mean monthly cost difference.

Indicates P-value < .05.

Health care costs for the weighted populations were obtained by using inverse probability of treatment weights. The inverse probability of treatment weights were estimated based on propensity score. Variables used in the propensity score calculation included the following baseline characteristics: age, gender, region, quarter and year of index date, insurance plan type, time from first chronic lymphocytic lymphoma diagnosis to index date, Charlson comorbidity index, comorbidities (hypertension, lymphoma, deficiency anemias, diabetes, coagulation deficiency, chronic pulmonary disease), and baseline use of corticosteroids.

The 6-month period spanned from the initiation of front-line therapy up to 6 months after initiation. Even if treatment was stopped or changed to another regimen, the evaluation continues until the end of the 6-month period.

Cost differences were calculated using weighted generalized linear models with normal distribution. Models were adjusted for baseline total all-cause costs.

CIs and P-values were obtained from non-parametric bootstrap procedures using 500 replicates.

Cancer-related medical costs were defined as claims with a primary or secondary diagnosis for cancer (International Classification of Diseases, Ninth Edition Clinical Modification codes: 140-239; International Classification of Diseases, Tenth Edition Clinical Modification codes: C00-D49). Cancer-related pharmacy costs were defined as costs of antineoplastic agents and of corticosteroids commonly used with antineoplastic agents (ie, prednisone, dexamethasone, and methylprednisolone).